Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Rationale for Clinically Guided Dose Titration to Optimize Individual Response

Mavacamten is the first and only cardiac myosin inhibitor approved in 5 continents for the treatment of adults with symptomatic New York Heart Association class II and III obstructive hypertrophic cardiomyopathy. An evidence‐based rationale was used to develop individualized mavacamten dosing, guide...

Полное описание

Библиографические подробности

Главные авторы:	Anjali T. Owens, Milind Desai, Matthew T. Wheeler, Anna Rodonski, Samira Merali, Amy J. Sehnert, Sara Saberi
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Wiley 2024-09-01
Серии:	Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Предметы:	echocardiogram individualized dosing left ventricular ejection fraction left ventricular outflow tract gradient mavacamten obstructive hypertrophic cardiomyopathy
Online-ссылка:	https://www.ahajournals.org/doi/10.1161/JAHA.124.033767
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!